SYNOESIS THERAPEUTICS LTD
About
SyNoesis Therapeutics is a European biotechnology company developing first-in-class small-molecule therapies for neurodegenerative diseases. Our lead program targets the Nurr1:RXRα pathway, a key regulator of neuronal survival, neuroinflammation, and proteostasis, with the goal of delivering disease-modifying treatments for Parkinson’s disease and related neurodegenerative disorders.
The company combines expertise in drug discovery, translational neuroscience, biophysics, AI-enabled medicinal chemistry, and biomarker development. Our Nurr1 platform has demonstrated in vivo target engagement, neuroprotective activity, and a differentiated mechanism supporting neuronal resilience and protein homeostasis.
Recent achievements include selection for the EIC Pre-Accelerator, support from the BaseLaunch venture program in Switzerland, advancement of multiple candidate series toward clinical candidate nomination, and strategic collaborations with leading translational drug discovery organizations, including the Oxford Drug Discovery Institute (ODDI).
SyNoesis is actively seeking pharmaceutical partners for co-development, licensing, and translational collaborations.
Business Domain / 分野
Business Type / 業種
Modalities / モダリティ
Disease Area / 疾患領域
Technologies / 技術
Additional Information
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術